Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens (WBA) delivered earnings and revenue surprises of 5.45% and 4.16%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Q2 Earnings and Revenues Surpass Estimates

Walgreens quarterly profits fell more than 20% to $703 million thanks to “lower COVID-19 vaccine and testing volumes.”

Walgreens Profits Dip To $703 Million On Lower Covid ‘Vaccine And Testing Volumes'

The retail pharmacy posts second-quarter adjusted earnings of $1.16 a share, topping analysts' expectations of $1.10.

Walgreens Stock Rises on Earnings Beat

Walgreens' quarterly results topped Wall Street's expectations, even as profit declined from a year earlier.

Walgreens revenue rises despite sharp decline in demand for Covid tests, vaccines

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA today announced financial results for the second quarter of fiscal 2023.

Walgreens Boots Alliance Reports Fiscal 2023 Second Quarter Results

Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

General Electric

Dividend stocks drop by the dividend amount on the ex-dividend date. The stock takes a short-term hit, but the shareholders are compensated in cash on the payout date.

Dividends, Short-Term Pain, but Long-Term Gain?

PayPal

Sirius XM Holdings Inc

Although bear market declines can be painful in the short-term, they unearth amazing opportunities for patient investors. Based on Wall Street's forward earnings estimates, these Nasdaq 100 components are the cheapest they've ever been and are ripe for the picking.

3 Nasdaq 100 Stocks That Have Never Been This Cheap

Leonardo DRS Inc

In early trading on Friday, the Dow Jones industrials were down 0.55%, the S&P 500 down 0.50% and the Nasdaq down 0.41%.

Earnings Previews: Leonardo DRS, Walgreens

Walgreens Boots Alliance (WBA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Walgreens Boots Alliance (WBA) This Earnings Season?

Although we expect the company to post a downbeat Q2, we believe its stock has more room for growth, as discussed below Our interactive dashboard analysis on Walgreens Earnings Preview has additional details.

What To Expect From Walgreens' Q2?

Two analysts trimmed their price targets on the stock. Both reduced their levels by $1 per share.

Why Walgreens Boots Alliance Stock Weakened on Wednesday

Carnival

Core & Main

Concentrix Corporation 

Cintas Corp

McCormick

Micron Technology

Paychex

SYNNEX

Buying stocks before the earnings announcement is tricky, and there are several reasons for that.

10 Biggest Companies Reporting Earnings in the Fifth Week of March 2023

Walgreens (WBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Walgreens Boots Alliance (WBA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Recently, Zacks.com users have been paying close attention to Walgreens (WBA). This makes it worthwhile to examine what the stock has in store.

Is Trending Stock Walgreens Boots Alliance, Inc. (WBA) a Buy Now?

CVS Health

If you're looking for passive income, these two dividend stocks might be excellent options.

Best Dividend Stock to Buy: Walgreens vs. CVS

Amgen

Diamondback Energy

Gilead Sciences

Kraft Heinz

The Nasdaq had a dreadful 2022, down a stunning 33% for the year. While the tech-heavy index has started off 2023 much better, up 5.9% as of the close Thursday, many investors are extremely nervous, especially given the recent uncertainty with the banking industry.

The 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Spring Break Rally

CareTrust REIT

Walgreens Boots Alliance expects a strong second half of 2023. CareTrust REIT has raised its dividend every year since it went public in 2014.

2 Healthcare Dividend Stocks That Hit the Sweet Spot

Enterprise Products Partners

Loathe stock market volatility? Buying stakes in profitable businesses with a long history of outperformance can be a smart move.

3 Exceptionally Safe Stocks That Can Turn $400,000 Into $1 Million by 2030

Citigroup

Dow Inc

Energy Transfer LP Unit

Altria

Newell Brands

AT&T

It never fails. Just when it seems like the financial world has things in good working order, the Silicon Valley Bank episode emerges, and in a quick 48 hours it is game over.

Bearish Morgan Stanley Strategist Says Sell the Rally Now: 7 Ultra-Safe Stocks With Huge Dividends

WBA has been investing a lot in its healthcare segment through acquisitions. The company is looking to become an integrated healthcare-pharmacy services company.

Walgreens Looks Towards Healthcare Segment To Renew Growth

Walgreens has experienced a significant decline in its stock since 2015 due to the margin compression, but the market may have been too harsh on the company. Despite reimbursement pressures, WBA's recent shift in strategy and acquisition could provide growth opportunities.

Walgreens: Overpunished And Offering An Attractive Dividend

Intel

Johnson & Johnson

The iconic Dow Jones Industrial Average was the top-performing major U.S. stock index in 2022. Though the Dow has 30 components, three stand out for being historically cheap.

These 3 Dow Stocks Are the Cheapest They've Been in Over a Decade

Global Payments

Medtronic

Unilever

Verizon

Although the biggest and most-established enterprises generally outperform smaller firms during troubled times, this concept doesn't always ring true, meaning that speculators can target beaten-down blue-chip stocks to buy. To be sure, a few advantages exist in targeting this sector over a lesser-capitalized fare.

7 Blue-Chip Stocks to Buy at an All-Time Low

Amcor Plc

Franklin Resources

Cardinal Health

Chevron

Essex Property Trust

Federal Realty Investment Trust

Realty Income Corp

Sysco

T. Rowe Price Group

V.F.

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." --Kiplinger.com/Investing. 67 Aristocrats screened as of March 8, 2023, represented all eleven Morningstar Sectors. Broker estimated top ten net gains ranged 16.32%-32.64% topped by WBA & VFC.

News for Walgreens Stock (WBA)